AZ’ Farxiga hit with complete response letter
AstraZeneca has said that it will work closely with the FDA to discuss the next steps.
15th July 2019
Latest news
Success for GSK’s Zejula in ovarian cancer
The drug was found to demonstrate significant improvement in progression free survival for women regardless of their biomarker status.
15th July 2019
Gilead, Galapagos form $5.1b R&D partnership
Galapagos will receive a $3.95 billion upfront payment and a $1.1 billion equity investment from Gilead, which it will use to expand and accelerate its research and development programs.
15th July 2019
NICE recommends Skyrizi, Forxiga
The recommendations are for the indication of plaque psoriasis and type I diabetes, respectively.
15th July 2019
Record number of children hospitalised for eating disorders
An overwhelming 91% of those admitted were of girls, and 1,326 of them were girls aged 13 to 17 years.
15th July 2019
Immune cell discovery could help provide endometriosis relief
Currently, endometriosis treatment options are limited to surgical removal of lesions or medical management to suppress ovarian hormone production.
12th July 2019
Another Alzheimer’s setback as Amgen, Novartis abandon BACE inhibitor trial
Sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk.
12th July 2019
Orphan Drug Designation granted for AZ’ Imfinzi
The decision comes hot on the heels of the Phase III CASPIAN trial, which met its primary endpoint.
12th July 2019
Experts identify six ways to speed up dementia research
The work, funded by Alzheimer’s Research UK, calls for a fresh focus on how research is conducted.
12th July 2019
Pairing targeted drugs could overcome breast, lung cancer treatment resistance
The new data could broaden the clinical use of palbociclib – and other drugs that work in the same way – beyond breast cancer to include many other tumour types as well.
12th July 2019
BMJ data suggests link between sugary drinks and cancer
100 ml increase in sugary drinks each day was associated with an 18% increased risk of overall cancer and a 22% increased risk of breast cancer.
11th July 2019
FDA set to review Sanofi’s isatuximab for multiple myeloma
Multiple myeloma is the second most common hematologic malignancy, affecting more than 138,0002 people worldwide.
11th July 2019
Nursing degree applications at 'crisis point'
Applications in England have fallen 29% since the bursary was removed in 2016.
11th July 2019
NIHR to invest £135m to tackle system challenges
The five-year plan will join up some of the country’s best universities, leading innovators and local authorities to solve some of the biggest issues facing health and social care.
11th July 2019
NICE recommends gammaCore for cluster headaches
The portable technology aims to modify pain signals by stimulating the vagus nerve through the skin of the neck.
11th July 2019
